Minerva Neurosciences Reports Third Quarter 2016 Financial Results And Business Updates

Published: Nov 03, 2016

WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the third quarter ended September 30, 2016.

“Recent highlights for Minerva include the completion and analyses of positive data from the 24-week open label extension phase of our Phase IIb trial with MIN-101 for schizophrenia announced on October 26 and the acceptance of four abstracts for presentation at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), including a featured oral presentation of data from the MIN-101 trial,” said Dr. Remy Luthringer, president and chief executive officer of Minerva.

Back to news